Literature DB >> 26194492

Medication persistence in older women with osteoporosis: a pilot study.

C Gillette1, D M Howerton2, B D Williams3, M A Mahmood4.   

Abstract

UNLABELLED: Most osteoporosis patients stop their medications before they should. Side effects are the most common reason patients in this sample stopped their medication before they told their physician. Physicians should use shared decision-making and discuss side effects of osteoporosis medications with their patients and explain the risks of the medications.
INTRODUCTION: The aims of this study were to (a) qualitatively examine reasons for medication non-persistence in osteoporosis, and (b) investigate how medication non-persistence in osteoporosis is associated with outcome expectations, self-efficacy, trust in physicians, and health locus of control.
METHODS: Subjects were recruited from online support groups to answer an anonymous online survey. Subjects were eligible if they (a) were female, (b) were at least 40 years of age, (c) self-identify as having osteoporosis, and (d) have taken at least one medication for osteoporosis. During the survey, subjects completed measures of self-efficacy, outcome expectations, trust in physicians generally, health locus of control, and demographic information.
RESULTS: Thirty-four subjects completed the online survey and had usable data. Approximately 82 % (n = 28) of subjects reported discontinuing an osteoporosis medication without first consulting a physician. The most common reason patients discontinued an osteoporosis medication was adverse effects. Subjects were more likely to discontinue their medications when they had poorer outcome expectations on average (p = 0.01), had lower trust in physicians on average (p < 0.0001), and had more of a doctors-centered locus of control (p = 0.03). Self-efficacy, age, insurance, status, and other measures of locus of control were not associated with medication non-persistence.
CONCLUSIONS: Side effects are a significant concern for women with osteoporosis and may be a cause for medication non-persistence.

Entities:  

Keywords:  Adverse effects; Medication persistence; Osteoporosis

Mesh:

Substances:

Year:  2015        PMID: 26194492     DOI: 10.1007/s00198-015-3242-7

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  15 in total

1.  Trust in the medical profession: conceptual and measurement issues.

Authors:  Mark A Hall; Fabian Camacho; Elizabeth Dugan; Rajesh Balkrishnan
Journal:  Health Serv Res       Date:  2002-10       Impact factor: 3.402

2.  Provider-caregiver-child discussions about risks associated with asthma control medications: content and prevalence.

Authors:  Chris Gillette; Susan J Blalock; Jaya K Rao; Dennis Williams; Ceila E Loughlin; Betsy Sleath
Journal:  Pediatr Pulmonol       Date:  2013-09-20

Review 3.  Extra-skeletal effects of bisphosphonates.

Authors:  Addolorata Corrado; Nella Santoro; Francesco Paolo Cantatore
Journal:  Joint Bone Spine       Date:  2006-12-04       Impact factor: 4.929

4.  Medical costs of osteoporosis in the elderly Medicare population.

Authors:  S W Blume; J R Curtis
Journal:  Osteoporos Int       Date:  2010-12-17       Impact factor: 4.507

Review 5.  Bisphosphonate-associated scleritis: a case report and review.

Authors:  Sophia Leung; Bimal H Ashar; Redonda G Miller
Journal:  South Med J       Date:  2005-07       Impact factor: 0.954

6.  Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome.

Authors:  N Yarom; R Yahalom; Y Shoshani; W Hamed; E Regev; S Elad
Journal:  Osteoporos Int       Date:  2007-06-28       Impact factor: 4.507

7.  Adherence and profile of non-persistence in patients treated for osteoporosis--a large-scale, long-term retrospective study in The Netherlands.

Authors:  J C Netelenbos; P P Geusens; G Ypma; S J E Buijs
Journal:  Osteoporos Int       Date:  2010-09-14       Impact factor: 4.507

8.  Abandoned acid? Understanding adherence to bisphosphonate medications for the prevention of osteoporosis among older women: a qualitative longitudinal study.

Authors:  Charlotte Salter; Lisa McDaid; Debi Bhattacharya; Richard Holland; Tarnya Marshall; Amanda Howe
Journal:  PLoS One       Date:  2014-01-02       Impact factor: 3.240

Review 9.  Challenges in implementing and maintaining osteoporosis therapy.

Authors:  Ankita Modi; Shiva Sajjan; Sampada Gandhi
Journal:  Int J Womens Health       Date:  2014-08-13

10.  Clinical efficacy and treatment persistence of monthly minodronate for osteoporotic patients unsatisfied with, and shifted from, daily or weekly bisphosphonates: the BP-MUSASHI study.

Authors:  A Sakai; S Ikeda; N Okimoto; H Matsumoto; K Teshima; Y Okazaki; F Fukuda; S Arita; H Tsurukami; M Nagashima; T Yoshioka
Journal:  Osteoporos Int       Date:  2014-06-05       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.